Developability Assessment
Developability assessment is a critical early-stage evaluation step for antibody and antibody-oligonucleotide conjugate (AOC) programs, helping identify molecular risks and optimize candidate selection before entering complex CMC development. Protheragen provides comprehensive developability assessment services to evaluate antibody candidates from multiple perspectives, including molecular properties, biophysical characteristics, manufacturability, stability, and potential development risks. Our integrated assessment strategy supports informed candidate selection and accelerates the transition from discovery to IND-enabling development.
Overview of Developability Assessment
Developability assessment is an essential early-stage evaluation process in antibody and antibody-oligonucleotide conjugate (AOC) development, designed to characterize molecular properties and identify potential risks that may affect downstream development and manufacturing. By assessing factors such as structural stability, aggregation tendency, expression potential, solubility, and manufacturability, developability studies help determine whether a candidate molecule has suitable characteristics for further CMC development.
For antibody therapeutics, developability assessment typically evaluates critical molecular attributes associated with product quality, process feasibility, and formulation suitability. For AOC molecules, additional considerations are required due to the complexity introduced by antibody–oligonucleotide conjugation, including conjugation stability, payload compatibility, and overall molecular integrity.
A comprehensive developability assessment integrates computational analysis, biochemical evaluation, and biophysical characterization to support candidate selection, reduce development risks, and establish an effective development strategy before advancing into cell line development, process optimization, and IND-enabling studies.
Fig.1 Key factors affecting developability assessment. (Zhang W, et al., 2022)
Our Services
Our developability assessment services cover critical evaluation areas including molecular characteristics, stability profiles, manufacturability, and AOC-specific development considerations. These integrated assessments provide valuable insights for candidate selection and establish a strong foundation for subsequent process development and regulatory preparation.
Sequence-Based Developability Evaluation
Early sequence analysis provides valuable insights into potential molecular risks before experimental development.
Our services include:
- Antibody sequence analysis and optimization evaluation
- Identification of chemical modification liabilities
- Assessment of aggregation-prone regions
- Immunogenicity risk prediction
- Evaluation of developability-related sequence characteristics
These analyses support rational candidate selection and reduce risks during later-stage process development.
Biophysical Property Assessment
Comprehensive biophysical characterization helps determine the stability and behavior of antibody molecules under different conditions.
Key evaluations include:
- Thermal stability analysis
- Aggregation tendency assessment
- Solubility evaluation
- Colloidal stability analysis
- Viscosity assessment
Advanced analytical platforms are used to understand molecular behaviors associated with formulation feasibility and manufacturing performance.
Expression & Manufacturability Assessment
Manufacturability evaluation helps determine whether antibody candidates can be efficiently produced at laboratory and commercial scales.
Assessment areas include:
- Expression potential evaluation
- Protein yield assessment
- Purification feasibility analysis
- Process compatibility evaluation
- Scale-up risk assessment
Early identification of manufacturing challenges enables optimization of upstream and downstream development strategies.
Stability & Stress Evaluation
Understanding antibody stability profiles is essential for formulation development and long-term product quality.
Protheragen provides stress testing evaluations including:
- Thermal stress studies
- Freeze-thaw stability assessment
- Agitation stress evaluation
- Light stress testing
- Accelerated stability assessment
These studies provide critical information for formulation selection and storage condition development.
AOC-Specific Developability Assessment
For antibody-oligonucleotide conjugates, additional evaluation is required due to the complexity introduced by oligonucleotide payloads and conjugation chemistry.
Protheragen supports AOC candidate assessment through:
- Antibody-conjugate stability evaluation
- Conjugation compatibility assessment
- Drug-to-antibody ratio (DAR) analysis strategy
- Payload distribution evaluation
- Linker stability assessment
These assessments help optimize AOC molecular design and improve the probability of successful CMC development.
Key Capabilities
Protheragen integrates advanced analytical platforms, multidisciplinary expertise, and comprehensive CMC development experience to provide reliable developability assessment solutions for antibody and AOC candidates. Our capabilities cover molecular property evaluation, biophysical characterization, manufacturability assessment, and stability analysis, enabling early identification of potential development challenges and supporting data-driven candidate selection.
Through systematic assessment of critical quality attributes (CQAs) and development risks, Protheragen helps optimize candidate molecules and establish robust development strategies for subsequent process development, analytical characterization, and regulatory submission.
| Assessment Area |
Evaluation Focus |
| Molecular Analysis |
Sequence liabilities, structural risks, immunogenicity assessment |
| Biophysical Characterization |
Stability, aggregation, solubility, viscosity |
| Manufacturability Assessment |
Expression potential, purification feasibility, process risks |
| Stability Evaluation |
Stress response, storage stability, formulation suitability |
| AOC Evaluation |
Conjugation compatibility, DAR profile, linker/payload stability |
Supporting Technologies & Platforms
Protheragen utilizes integrated analytical technologies to support antibody developability assessment, including:
- Dynamic Light Scattering (DLS)
- Differential Scanning Calorimetry (DSC)
- Size Exclusion Chromatography (SEC-HPLC)
- LC-MS analysis
- Capillary Electrophoresis (CE-SDS)
- Protein concentration and purity analysis
These platforms enable comprehensive evaluation of molecular quality attributes and development risks.
Why Choose Us
Selecting the right therapeutic candidate at an early development stage is critical for reducing downstream risks and accelerating clinical translation. Protheragen provides integrated developability assessment solutions for antibody and AOC programs by combining molecular evaluation expertise, advanced analytical technologies, and CMC development experience. Our multidisciplinary approach enables comprehensive understanding of candidate properties, supports informed decision-making, and helps establish a robust development pathway from early discovery to IND-enabling studies.
- Comprehensive Candidate Evaluation Strategy
Protheragen evaluates antibody and AOC candidates through a systematic assessment framework covering molecular characteristics, structural stability, manufacturability, and formulation-related properties. This integrated strategy helps identify potential development challenges at an early stage and supports optimal candidate selection.
- Advanced Analytical Characterization Platforms
Our developability assessment services are supported by advanced analytical technologies for evaluating critical quality attributes (CQAs), including molecular integrity, aggregation behavior, thermal stability, purity, and structural characteristics. These insights provide essential data for process development and regulatory preparation.
- Expertise in Antibody and AOC Development
With experience in biologics and conjugated therapeutic development, Protheragen understands the unique challenges associated with antibody and AOC molecules. Our assessment strategies consider antibody properties as well as AOC-specific factors, including conjugation compatibility, molecular stability, and payload-related risks.
- Seamless Integration with CMC Development
Developability assessment results are closely connected with subsequent CMC activities, including cell line development, process optimization, analytical method development, and GMP manufacturing. Protheragen helps translate early characterization data into actionable development strategies to accelerate the progression of antibody and AOC candidates.
Early developability assessment provides valuable insights into candidate quality, manufacturability, and regulatory expectations. Protheragen combines scientific expertise, advanced analytical platforms, and CMC development experience to help clients identify optimal antibody and AOC candidates and accelerate progression toward IND submission and clinical development. Contact us to explore integrated developability assessment solutions for your next-generation antibody and AOC programs.
Reference
- Zhang W, et al. "Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics" Antib Ther. 2022; 6(1):13-29.
